BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-07 |
2024-09 |
-0.07 |
N/A |
N/A |
N/A |
2024-08-05 |
2024-06 |
-0.19 |
-0.06 |
0.13 |
68.42% |
2024-05-06 |
2024-03 |
-0.23 |
-0.17 |
0.06 |
26.09% |
2024-02-26 |
2023-12 |
-0.24 |
-0.28 |
-0.04 |
-16.67% |
2023-11-02 |
2023-09 |
-0.25 |
-0.19 |
0.06 |
24.00% |
2023-08-03 |
2023-06 |
-0.25 |
-0.24 |
0.01 |
4.00% |
Date |
Firm |
Action |
From |
To |
2023-09-24 |
RBC Capital |
Upgrade |
Outperform |
Outperform |
2023-09-17 |
RBC Capital |
Upgrade |
Sector Perform |
Outperform |
2023-08-03 |
RBC Capital |
Upgrade |
Sector Perform |
Sector Perform |
2023-08-03 |
Jefferies |
Upgrade |
Hold |
Buy |
2023-08-03 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-02 |
Needham |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-06-11 |
ABERCROMBIE GEORGE B |
Director |
36.43K |
Stock Award(Grant) |
2024-06-11 |
ASELAGE STEPHEN J |
Director |
72.66K |
Stock Award(Grant) |
2024-06-11 |
GALSON STEVEN K |
Director |
58.37K |
Stock Award(Grant) |
2024-06-13 |
HEGGIE THERESA |
Director |
52.85K |
Sale |
2024-06-11 |
HUTSON NANCY J |
Director |
93.64K |
Stock Award(Grant) |
2024-06-11 |
LEVIN ALAN G |
Director |
51.77K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
15.50M |
109.09M |
8.18% |
2023-06-29 |
Vanguard Group Inc |
15.09M |
106.23M |
7.96% |
2023-06-29 |
Baker Brothers Advisors, LLC |
12.71M |
89.48M |
6.71% |
2023-06-29 |
State Street Corporation |
12.26M |
86.34M |
6.47% |
2023-06-29 |
Avoro Capital Advisors LLC |
12.06M |
84.87M |
6.36% |
2023-06-29 |
Assenagon Asset Management S.A. |
5.33M |
37.54M |
2.81% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
8.22M |
58.41M |
4.34% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
5.86M |
41.26M |
3.09% |
2023-08-30 |
iShares Russell 2000 ETF |
4.29M |
30.51M |
2.26% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
2.81M |
19.96M |
1.48% |
2023-06-29 |
Vanguard Extended Market Index Fund |
2.58M |
18.14M |
1.36% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
2.44M |
17.17M |
1.29% |
Dividend |
Date |
0 |
2014-06-11 |
0 |
2014-06-05 |
0 |
2014-05-20 |
0 |
2014-05-16 |
0 |
2014-04-02 |